Renaissance Technologies
KPTI icon

Renaissance Technologies’s Karyopharm Therapeutics KPTI Stock Holding History

Renaissance Technologies’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
108,214
+2,800
+3% +$24.3K ﹤0.01% 2285
2026
Q1 		$587K Buy
105,414
+45,500
+76% +$347K ﹤0.01% 2533
2025
Q4 		$441K Sell
59,914
-4,800
-7% -$29.4K ﹤0.01% 2624
2025
Q3 		$423K Sell
64,714
-1,100
-2% -$5.92K ﹤0.01% 2863
2025
Q2 		$284K Buy
65,814
+4,600
+8% +$22.6K ﹤0.01% 3061
2025
Q1 		$229K Sell
61,214
-18,959
-24% -$162K ﹤0.01% 3040
2024
Q4 		$813K Sell
80,173
-2,587
-3% -$31.3K ﹤0.01% 2601
2024
Q3 		$1.03M Buy
82,760
+32,345
+64% +$402K ﹤0.01% 2429
2024
Q2 		$656K Sell
50,415
-10,038
-17% -$166K ﹤0.01% 2554
2024
Q1 		$1.37M Sell
60,453
-70,505
-54% -$1.24M ﹤0.01% 2278
2023
Q4 		$1.7M Buy
130,958
+82,265
+169% +$1.11M ﹤0.01% 2052
2023
Q3 		$979K Buy
48,693
+4,200
+9% +$94.3K ﹤0.01% 2315
2023
Q2 		$1.2M Sell
44,493
-4,554
-9% -$196K ﹤0.01% 2361
2023
Q1 		$2.86M Buy
49,047
+36,427
+289% +$1.8M ﹤0.01% 1800
2022
Q4 		$644K Sell
12,620
-7,933
-39% -$550K ﹤0.01% 2795
2022
Q3 		$1.68M Sell
20,553
-9,767
-32% -$730K ﹤0.01% 2133
2022
Q2 		$2.05M Buy
30,320
+15,980
+111% +$1.47M ﹤0.01% 2170
2022
Q1 		$1.58M Buy
14,340
+8,613
+150% +$1.07M ﹤0.01% 2410
2021
Q4 		$552K Sell
5,727
-27,300
-83% -$2.72M ﹤0.01% 3029
2021
Q3 		$2.88M Buy
33,027
+31,796
+2,583% +$3.3M ﹤0.01% 1813
2021
Q2 		$191K Buy
+1,231
New +$179K ﹤0.01% 3256
2020
Q3 		– Sell
-12,120
Closed -$3.44M – 3531
2020
Q2 		$3.44M Sell
12,120
-23,480
-66% -$6.94M ﹤0.01% 1854
2020
Q1 		$10.3M Buy
35,600
+24,900
+233% +$6.87M 0.01% 1145
2019
Q4 		$3.08M Buy
+10,700
New +$2.32M ﹤0.01% 2112
2019
Q3 		– Sell
-4,901
Closed -$440K – 3571
2019
Q2 		$440K Sell
4,901
-56,352
-92% -$4.52M ﹤0.01% 3043
2019
Q1 		$5.37M Buy
61,253
+32,836
+116% +$3.64M ﹤0.01% 1761
2018
Q4 		$3.99M Buy
28,417
+23,704
+503% +$4M ﹤0.01% 1861
2018
Q3 		$1.2M Sell
4,713
-4,480
-49% -$1.24M ﹤0.01% 2529
2018
Q2 		$2.34M Buy
+9,193
New +$2.27M ﹤0.01% 2187

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies's KPTI Position: Q2 2026 in Review

Renaissance Technologies increased its Karyopharm Therapeutics (KPTI) stake by 2.7% in Q2 2026, buying an estimated $24.3K and bringing the position to 108,214 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #2285.

Renaissance Technologies first reported a position in KPTI in Q2 2018 and has held it in 29 quarters since. The position peaked at $10.3M in Q1 2020. 96 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Renaissance Technologies held 108,214 shares of Karyopharm Therapeutics worth $1.06M as of Q2 2026.
  • Renaissance Technologies bought 2,800 Karyopharm Therapeutics shares in Q2 2026, an estimated $24.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q2 2026, its #2285 holding.
  • Renaissance Technologies first reported a position in Karyopharm Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Renaissance Technologies's Karyopharm Therapeutics position peaked at $10.3M in Q1 2020.
  • 96 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.